Published in Heart Fail Rev on July 01, 2013
Inequity of access to ACE inhibitors in Swedish heart failure patients: a register-based study. J Epidemiol Community Health (2015) 0.75
Novel Endpoints for Heart Failure Clinical Trials. Curr Heart Fail Rep (2017) 0.75
Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies. Heart Fail Rev (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 83.16
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA (1995) 45.41
Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics (2000) 19.26
Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med (2006) 17.13
Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr (2009) 14.63
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62
Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med (2001) 8.17
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J (2006) 4.10
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation (2007) 2.95
Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol (2006) 2.61
Methods for combining randomized clinical trials: strengths and limitations. Stat Med (1987) 2.49
Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol (2012) 2.41
Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med (2000) 2.00
Congestive heart failure with preserved systolic function in a statewide sample of community hospitals. J Card Fail (2001) 1.68
Correlates and outcomes of preserved left ventricular systolic function among older adults hospitalized with heart failure. Am Heart J (2002) 1.18
The association between blood pressure and mortality in patients with heart failure. Am Heart J (2006) 1.17
Differential prognostic effect of systolic blood pressure on mortality according to left-ventricular function in patients with acute heart failure. Eur J Heart Fail (2010) 1.12
Increased proximal arterial stiffness and cardiac response with moderate exercise in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol (2012) 1.09
Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease. Circ Heart Fail (2011) 1.00
Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension (2006) 0.92
The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovasc Drugs Ther (2003) 0.89
Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: a complex relationship. Am Heart J (2011) 0.86
Association of blood pressure at hospital discharge with mortality in patients diagnosed with heart failure. Circ Heart Fail (2009) 0.85
Angiotensin-converting enzyme inhibitors prescription is associated with longer survival among patients hospitalized for congestive heart failure who have preserved systolic function: a long-term follow-up study. J Card Fail (2006) 0.81
Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Res (2000) 0.81
Prognostic impact of angiotensin-converting enzyme inhibitor therapy in diastolic heart failure. Am J Cardiol (2008) 0.77
Effect of angiotensin-converting inhibitor or angiotensin receptor blocker on one-year survival in patients >or=65 years hospitalized with a left ventricular ejection fraction >or=50%. Am J Cardiol (2003) 0.76
Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. Am Heart J (1997) 0.76
Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40
Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol (2008) 7.04
Obesity paradox in patients with hypertension and coronary artery disease. Am J Med (2007) 5.61
Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet (2008) 5.05
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA (2012) 4.92
Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med (2007) 4.20
Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ (2013) 3.98
Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation (2011) 3.81
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA (2004) 3.20
A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol (2007) 3.07
Atrial fibrillation and obesity--results of a meta-analysis. Am Heart J (2007) 2.86
Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol (2010) 2.77
Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med (2010) 2.33
J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J (2010) 2.32
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens (2014) 2.28
Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) (2012) 2.16
Visceral angioedema due to angiotensin-converting enzyme inhibitor therapy. Cleve Clin J Med (2011) 2.09
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension (2004) 1.90
A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med (2003) 1.83
Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol (2007) 1.76
Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med (2011) 1.66
Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol (2004) 1.52
Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol (2008) 1.52
Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II. J Hypertens (2007) 1.51
Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST. Stroke (2007) 1.46
Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression. J Hypertens (2012) 1.45
Antihypertensive therapy and new onset diabetes. J Hypertens (2004) 1.45
Authors' reply to Laragh and Sealey. BMJ (2013) 1.40
Of millimeterology and cannibalism: comparative antihypertensive efficacy of angiotensin receptor blockers. Am Heart J (2003) 1.39
A suspicious stroke. Am J Med (2008) 1.39
The renin-angiotensin systems: evolving pharmacological perspectives for cerebroprotection. Curr Pharm Des (2005) 1.39
Trials on the effect of cardiac resynchronization on arterial blood pressure in patients with heart failure. Am J Cardiol (2010) 1.38
Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke (2006) 1.33
Left ventricular geometry and survival in patients with normal left ventricular ejection fraction. Am J Cardiol (2006) 1.32
Alcohol consumption and the risk of hypertension in men and women: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) (2012) 1.29
Left ventricular geometry and mortality in patients >70 years of age with normal ejection fraction. Am J Cardiol (2006) 1.26
Beyond salt: lifestyle modifications and blood pressure. Eur Heart J (2011) 1.24
Salt and hypertension: is salt dietary reduction worth the effort? Am J Med (2012) 1.22
Disparate effects of left ventricular geometry and obesity on mortality in patients with preserved left ventricular ejection fraction. Am J Cardiol (2007) 1.21
Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med (2010) 1.17
Is there an association between hypertension and cancer mortality? Am J Med (2002) 1.15
Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med (2012) 1.14
Hypertension management 2011: optimal combination therapy. Eur Heart J (2011) 1.13
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol (2006) 1.12
Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. Eur Heart J (2009) 1.09
Optimal renin-angiotensin system blockade-wishful thinking? Nat Rev Cardiol (2013) 1.08
Hypertension guidelines: political correctness trumping expertise? Hypertension (2014) 1.06
International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol (2013) 1.05
Oxidative stress and endothelial function: therapeutic interventions. Recent Pat Cardiovasc Drug Discov (2011) 1.05
Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials. J Hypertens (2011) 1.01
Potential pathogenic inflammatory mechanisms of endothelial dysfunction induced by type 2 diabetes mellitus. Curr Pharm Des (2011) 1.01
Compliance and fixed-dose combination therapy. Curr Hypertens Rep (2007) 1.00
Antihypertensive effects of statins: a meta-analysis of prospective controlled studies. J Clin Hypertens (Greenwich) (2013) 0.99
Characteristics and outcomes of revascularized patients with hypertension: an international verapamil SR-trandolapril substudy. Hypertension (2009) 0.98
Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens (2009) 0.96
Takotsubo-like cardiomyopathy in pheochromocytoma. Int J Cardiol (2011) 0.96
Calcium antagonists. Prog Cardiovasc Dis (2004) 0.95
Candidate gene polymorphisms and the 9p21 locus in acute coronary syndromes. Trends Mol Med (2008) 0.95
Fibrinogen and cardiovascular disease: genetics and biomarkers. Blood Rev (2011) 0.93
Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. Hypertension (2008) 0.92
Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark? Circulation (2009) 0.92
Gun ownership and firearm-related deaths. Am J Med (2013) 0.91
ALTITUDE trial and dual RAS blockade: the alluring but soft science of the surrogate end point. Am J Med (2013) 0.90
Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European society of cardiology. Eur Heart J (2006) 0.90
Heart regeneration: what cells to use and how? Curr Opin Pharmacol (2008) 0.89
Hypertension and diabetes. Adv Cardiol (2008) 0.89
Blood pressure targets in patients with coronary artery disease: observations from traditional and Bayesian random effects meta-analysis of randomised trials. Heart (2012) 0.88
The j-point phenomenon in aggressive therapy of hypertension: new insights. Curr Atheroscler Rep (2012) 0.88
Hypertension in the elderly: some practical considerations. Cleve Clin J Med (2012) 0.88
Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol (2013) 0.87
Is there a role for erythropoietin in cardiovascular disease? Expert Opin Biol Ther (2010) 0.87
Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol (2012) 0.86
Discrepancies between office and ambulatory blood pressure: clinical implications. Am J Med (2009) 0.86
Treatment of hypertension in the elderly. N Engl J Med (2008) 0.86
Are fixed-dose combination antihypertensives suitable as first-line therapy? Curr Med Res Opin (2012) 0.85
Management of blood pressure in patients with diabetes. Am J Hypertens (2011) 0.85
Characteristics of contemporary patients with hypertension and coronary artery disease. Clin Cardiol (2004) 0.85
TIMPs, MMPs and cardiovascular disease. Eur Heart J (2004) 0.84
Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). Am J Cardiol (2010) 0.84
Beta-blockers as first-line antihypertensive therapy the crumbling continues. J Am Coll Cardiol (2009) 0.83
Long-term safety of antihypertensive therapy. Prog Cardiovasc Dis (2006) 0.83
Obesity, weight reduction and survival in heart failure. J Am Coll Cardiol (2002) 0.83
Erythrocyte membrane properties in patients with essential hypertension. Cell Biochem Biophys (2013) 0.83
Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. Am J Cardiol (2013) 0.82
Blood pressure and diabetes: vicious twins. Heart (2013) 0.82
From atherosclerosis to acute coronary syndromes: the role of soluble CD40 ligand. Trends Cardiovasc Med (2010) 0.82
Dual RAS blockade-unresolved controversy? Nat Rev Nephrol (2013) 0.81
Secondary prevention after ischemic stroke. N Engl J Med (2012) 0.81
Combined effects of fibrinogen genetic variability on atherosclerosis in patients with or without stable angina pectoris: focus on the coagulation cascade and endothelial function. Int J Cardiol (2013) 0.81
Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis. Am J Med (2009) 0.81
Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Fail Rev (2015) 0.81
Carcinogenicity of antihypertensive therapy. Curr Hypertens Rep (2002) 0.80
Conflicting effects of nitric oxide and oxidative stress in chronic heart failure: potential therapeutic strategies. Heart Fail Rev (2012) 0.80
Paradoxical hypertension with cardiac tamponade. Am J Cardiol (2012) 0.80
Beta-blocker therapy and depression. JAMA (2002) 0.80
Infusion of lin-/sca-1+ and endothelial progenitor cells improves proinflammatory and oxidative stress markers in atherosclerotic mice. Int J Cardiol (2012) 0.80